U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB


(MARK ONE)

[X]  QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2002

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934 FOR THE TRANSITION PERIOD FROM                TO


COMMISSION FILE NUMBER:


                       L.O.M. MEDICAL INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

DELAWARE                                                     98-0178784
(State or other jurisdiction of                              (I.R.S. Employer
incorporation or organization)                               Identification No.)


                       #3-1482 Springfield Road, Kelowna,
                        British Columbia, Canada V1Y 5V3
                    (Address of principal executive offices)

                                  250.762.7552
                (Issuer's Telephone Number, including Area Code)



                              Thomas E. Stepp, Jr.
                                 Stepp Law Group
                           1301 Dove Street, Suite 460
                         Newport Beach, California 92660
                             Telephone: 949.660.9700
                             Facsimile: 949.660.9010
            (Name, Address and Telephone Number of Agent for Service)


                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing  requirements for the past 90 days.
                                                                [X] Yes   [ ] No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity,  as of the latest  practical  date.  As of August 31,  2002,  there were
6,194,139  shares of the  issuer's  $.001  par value  common  stock  issued  and
outstanding.


<PAGE>










                                     PART I


Item 1.  Financial Statements
-----------------------------













                                   Consolidated Financial Statements of


                                   L.O.M. MEDICAL INTERNATIONAL INC.

                                   (A Development Stage Enterprise)

                                   Three months ended August 31, 2002

                                   (Unaudited)


























                                       F-1
<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Balance Sheets
$ United States

August 31, 2002 and May 31, 2002

=======================================================================================================
                                                                             August 31,         May 31,
                                                                                   2002            2002
                                                                            (Unaudited)
-------------------------------------------------------------------------------------------------------

Assets

Current assets:
<S>                                                                      <C>             <C>
    Cash and cash equivalents                                            $    147,458    $    142,114
    Amounts receivable                                                         22,933          18,933
    Prepaid expenses                                                            8,235           8,235
    ---------------------------------------------------------------------------------------------------
                                                                              178,626         169,282

Advances and deposits                                                           9,803           9,803

Fixed assets                                                                   25,562          28,564

Patent costs                                                                    3,126           4,168

-------------------------------------------------------------------------------------------------------
                                                                         $    217,117    $    211,817
=======================================================================================================

Liabilities and Stockholders' Deficiency

Current liabilities:
    Accounts payable and accrued liabilities (note 3)                    $    296,184    $    319,537

Minority interest                                                             282,681         288,491

Share subscriptions (note 2)                                                  224,184          34,375

Stockholders' deficiency:
    Capital stock
       5,000,000 preferred shares with a par value of $0.001
                   per share authorized
       50,000,000  common shares with a par value of $0.001
                   per share authorized, 6,194,139 issued
                   (May 31, 2002 - 6,178,446 issued), net of
                   treasury stock of 78,436 (May 31, 2002 - 83,731)             6,194           6,179
    Additional paid-in capital                                              3,503,519       3,464,159
    Deficit accumulated during the development stage                       (4,128,949)     (3,934,228)
    Accumulated other comprehensive income                                     33,304          33,304
-------------------------------------------------------------------------------------------------------
                                                                             (585,932)       (430,586)
Going concern (note 1 (a))
Commitments (note 3)
-------------------------------------------------------------------------------------------------------
                                                                         $    217,117    $    211,817
-------------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to consolidated financial statements







                                       F-2
<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Loss
$ United States

Three months ended August 31, 2002 and 2001 and period from inception
(March 17, 1997) to August 31, 2002
(Unaudited)

====================================================================================================
                                                  From inception    Three months ended, August 31,
                                                (March 17, 1997)    --------------------------------
                                              to August 31, 2002            2002              2001
----------------------------------------------------------------------------------------------------

<S>                                           <C>                 <C>               <C>
Expenses:
    General and administration                $      2,934,860    $      171,892    $       85,065
    Research and development                         1,316,609            23,103           231,316
    ------------------------------------------------------------------------------------------------
                                                     4,251,469           194,995           316,381

----------------------------------------------------------------------------------------------------
Loss, before other income                           (4,251,469)         (194,995)         (316,381)

Other income:
    Interest income                                    122,520               274             8,153

----------------------------------------------------------------------------------------------------
Loss                                          $     (4,128,949)   $     (194,721)   $     (308,228)
====================================================================================================


Weighted average number of common shares,
   basic and diluted                                 5,059,504         6,181,334         6,152,885

Loss per common share, basic and diluted      $          (0.82)   $        (0.03)   $        (0.05)
====================================================================================================
</TABLE>
See accompanying notes to consolidated financial statements



























                                       F-3
<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Cash Flows
($ United States)

Three months ended August 31, 2002 and 2001 and period from inception
(March 17, 1997) to August 31, 2002
(Unaudited)

===========================================================================================================================
                                                                     From inception         Three months ended August 31,
                                                                   (March 17, 1997)       -------------------------------
                                                                 to August 31, 2002                2002               2001
---------------------------------------------------------------------------------------------------------------------------

<S>                                                              <C>                  <C>                  <C>
Operating activities
   Loss for the period                                           $     (4,128,949)    $       (194,721)    $     (308,228)

   Items not involving cash
     Amortization                                                          89,289                4,044              4,610
     Gain on sale of fixed assets                                          (2,659)                   -                  -
     Write-down of product rights and patent costs                        374,128                    -                  -
     Subscriptions for common shares for consulting services               91,259               73,659                  -
     Compensation cost of stock options issued
       for services                                                       295,269                    -                  -
     Foreign exchange gain on redeemable preferred shares                 (19,046)              (5,810)           (17,400)
     Write-down of advances and deposits                                  168,680                    -                  -

   Changes in non-cash working capital
     Amounts receivable                                                   (22,933)              (4,000)            16,924
     Prepaid expenses                                                      (8,235)                   -             (3,684)
     Accounts payable and accrued liabilities                              76,986              (18,353)           (12,957)
     ----------------------------------------------------------------------------------------------------------------------
                                                                       (3,086,211)            (145,181)          (320,735)
Financing activities
     Issuance of capital stock                                          2,553,549                    -             22,100
     Common shares rescinded or repurchased                               (47,226)                   -                  -
     Proceeds from subscriptions for shares                             1,060,244              150,525             99,558
     ----------------------------------------------------------------------------------------------------------------------
                                                                        3,566,567              150,525            121,658
Investing activities
     Advances and deposits                                               (178,483)                   -             (2,500)
     Proceeds on disposition of fixed assets                                6,189                    -                  -
     Acquisition of fixed assets                                         (103,508)                   -             (1,164)
     Acquisition of product rights                                        (90,577)                   -                  -
     ----------------------------------------------------------------------------------------------------------------------
                                                                         (366,379)                   -             (3,664)

Effects of change in exchange rates on cash and cash
  equivalents                                                              33,481                    -                  -
---------------------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash and cash equivalents                          147,458                5,344           (202,741)

Cash and cash equivalents, beginning of period                                  -              142,114            741,152
---------------------------------------------------------------------------------------------------------------------------
Cash and cash equivalents, end of period                         $        147,458     $        147,458     $      538,411
===========================================================================================================================

Supplementary information
   Interest paid                                                 $              -     $              -     $            -
   Income taxes paid                                                            -                    -                  -
Non-cash financing and investing activities
   Issuance of redeemable preferred shares for product rights             309,677                    -                  -
   Common shares issued for conversion of share subscriptions             909,719               34,375              6,800
   Common shares issued for consulting services                            91,259               73,659                  -
   Common shares rescinded and cancelled                                   46,226                    -                  -
   Compensation cost of stock options issued for services                 295,269                    -                  -
   Unpaid amount related to rescinded shares (note 3)                     212,347                5,000                  -
   Unpaid amount related to returned shares                                 6,851                    -                  -
===========================================================================================================================
</TABLE>
See accompanying notes to consolidated financial statements


                                       F-4
<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Stockholders' Equity (Deficiency) and Comprehensive
Income
$ United States

For the period from inception on March 17, 1997 to August 31, 2002

==================================================================================================================================
                                              Capital Stock                         Deficit
                                         ----------------------                 Accumulated     Accumulated
                                             Number                Additional    During the           Other                Total
                                          of Common                   Paid in   Development   Comprehensive        Stockholders'
                                             Shares      Amount       Capital         Stage          Income  Equity (Deficiency)
----------------------------------------------------------------------------------------------------------------------------------

<S>                                       <C>        <C>         <C>           <C>           <C>             <C>
Common shares issued on incorporation             3  $        1  $          -  $          -  $            -  $                 1

Comprehensive income (loss):
  Loss                                            -           -             -      (138,272)              -             (138,272)
  Foreign currency translation                    -           -             -             -          13,582               13,582
----------------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                      (124,690)

----------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1997                             3           1             -      (138,272)         13,582             (124,689)

Common shares issued to founders
  and others at $0.001                    4,210,090       4,210             -             -               -                4,210

Common shares issued at $1.00
  net of share issue costs                  668,154         668       469,887             -               -              470,555

Common shares issued at $1.00 on
  conversion of share subscriptions         605,000         605       604,395             -               -              605,000

Comprehensive income (loss):
  Loss                                            -           -             -      (293,239)              -             (293,239)
  Foreign currency translation                    -           -             -             -          (7,294)              (7,294)
----------------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                      (300,533)

----------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1998                     5,483,247       5,484     1,074,282      (431,511)          6,288              654,543

Common shares issued on
  November 30, 1998 at $3.25
  net of share issue costs                   36,300          36        96,726             -               -               96,762

Comprehensive income (loss):
  Loss                                            -           -             -      (726,055)              -             (726,055)
  Foreign currency translation                    -           -             -             -          17,038               17,038
----------------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                      (709,017)

----------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1999                     5,519,547       5,520     1,171,008    (1,157,566)         23,326               42,288

Common shares issued on
  April 17, 2000 at $3.25
  net of share issue costs                  307,610         308       967,335             -               -              967,643

Common shares issued on
  May 10, 2000 at $3.25 on
  conversion of share
  subscriptions                              19,302          19        62,712             -               -               62,731

Comprehensive income (loss):
  Loss                                            -           -             -      (508,835)              -             (508,835)
  Foreign currency translation                    -           -             -             -           9,978                9,978
----------------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                      (498,857)

----------------------------------------------------------------------------------------------------------------------------------

Balance, May 31, 2000                     5,846,459  $    5,847  $  2,201,055  $ (1,666,401) $       33,304  $           573,805
==================================================================================================================================




                                       F-5
<PAGE>



<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Stockholders' Equity (Deficiency) and Comprehensive
Income (continued)
$ United States

For the period from inception on March 17, 1997 to August 31, 2002

==================================================================================================================================
                                              Capital Stock                         Deficit
                                         ----------------------                 Accumulated     Accumulated
                                             Number                Additional    During the           Other                Total
                                          of Common                   Paid in   Development   Comprehensive        Stockholders'
                                             Shares      Amount       Capital         Stage          Income  Equity (Deficiency)
----------------------------------------------------------------------------------------------------------------------------------
<S>                                       <C>        <C>         <C>           <C>           <C>             <C>
Balance, May 31, 2000,
  carried forward                         5,846,459  $    5,847  $  2,201,055  $ (1,666,401) $       33,304  $           573,805

Common shares issued on
  September 22, 2000 for
  cash at $3.25 net of share
  issue costs                               249,271         250       726,654             -               -              726,904

Common shares issued on
  December 19, 2000 at $3.25
  on conversion of share
  subscriptions                              57,081          57       185,456             -               -              185,513

Compensation costs for
  stock options issued for
  services                                        -           -       295,269             -               -              295,269

Comprehensive income (loss):
  Loss                                            -           -             -    (1,216,128)              -           (1,216,128)
  Foreign currency translation                    -           -             -             -               -                    -
----------------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                    (1,216,128)
----------------------------------------------------------------------------------------------------------------------------------

Balance, May 31, 2001                     6,152,811  $    6,154  $  3,408,434  $ (2,882,529) $       33,304  $           565,363

Common shares issued on
  August 31, 2001 at $3.25
  on conversion of share
  subscriptions                               6,800           7        22,093             -               -               22,100

Common shares issued for cash
  on October 11, 2001 at $3.25, net
  of share issue costs                       38,211          38       110,245             -               -              110,283

Common shares issued for cash
  on January 10, 2002 at $3.25                5,020           5        16,310             -               -               16,315

Common shares issued for cash
  on January 10, 2002 at $2.41               47,697          47       114,903             -               -              114,950

Common shares issued for consulting
  services rendered on January 10, 2002
  at $2.41                                    7,303           7        17,593             -               -               17,600

Shares rescinded and cancelled
  on February 22, 2002                      (18,702)        (19)      (46,207)            -               -              (46,226)

Common shares issued for cash
  on April 2, 2002 at $3.25                   2,880           3         9,357             -               -                9,360

Common shares issued for cash
  on April 2, 2002 at $2.41                  10,400          10        25,054             -               -               25,064



                                       F-6
<PAGE>



<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Stockholders' Equity and Comprehensive Income
(continued)
$ United States

Period from inception (March 17, 1997) to August 31, 2002

==================================================================================================================================
                                              Capital Stock                         Deficit
                                         ----------------------                 Accumulated     Accumulated
                                             Number                Additional    During the           Other                Total
                                          of Common                   Paid in   Development   Comprehensive        Stockholders'
                                             Shares      Amount       Capital         Stage          Income  Equity (Deficiency)
----------------------------------------------------------------------------------------------------------------------------------
<S>                                       <C>        <C>         <C>           <C>           <C>             <C>
Common shares issued for cash
  on April 2, 2002 at $1.00                  10,000          10         9,990             -               -               10,000

Common shares issued for cash
  on April 24, 2002 at $3.25                    462           1         1,501             -               -                1,502

Comprehensive loss:
  Loss                                            -           -             -    (1,051,699)              -           (1,051,699)
----------------------------------------------------------------------------------------------------------------------------------
                                          6,262,882       6,263     3,689,273    (3,934,228)         33,304             (205,388)

Shares rescinded and retained
  as treasury stock                         (81,231)        (81)     (217,266)            -               -             (217,347)

Shares repurchased and retained
  as treasury stock                          (3,205)         (3)       (7,848)            -               -               (7,851)
----------------------------------------------------------------------------------------------------------------------------------

Balance, May 31, 2002                     6,178,446  $    6,179  $  3,464,159  $ (3,934,228) $       33,304  $          (430,586)

Common shares issued on
  August 30, 2002 at $3.25 on conversion
  of share subscriptions, net of share
  issue costs                                10,693          10        34,365             -               -               34,375

Share rescission retracted (note 3)           5,000           5         4,995             -               -                5,000
Comprehensive loss:
  Loss                                            -           -             -      (194,721)              -             (194,721)

----------------------------------------------------------------------------------------------------------------------------------
Balance, August 31, 2002                  6,194,139  $    6,194  $  3,503,519  $ (4,128,949) $       33,304  $          (585,932)
==================================================================================================================================
</TABLE>




















                                       F-7
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
($ United States)

(Unaudited)

================================================================================

L.O.M.  Medical  International Inc. was incorporated on March 17, 1997 under the
General  Corporation  Laws of Delaware.  It con research and  development on new
products in the medical field including a retractable syringe.

1.   Significant accounting policies:
-------------------------------------

     a)   Going concern

          These  financial  statements  have been  prepared by management on the
          going concern basis in accordance with accounting principles generally
          accepted  in  the  United   States  of  America,   which  assumes  the
          realization of assets and  liquidation of liabilities  and commitments
          in the  normal  course  of  business.  As  shown  in the  consolidated
          financial statements,  to date, the Company has generated no revenues,
          has  a  working  capital   deficiency,   and  has  significant  unpaid
          commitments (note 3), and has accumulated a deficit since inception of
          $4,128,949. These factors, among others, raise substantial doubt about
          the Company's  ability to continue as a going  concern.  The Company's
          ability to continue as a going  concern is dependent on its ability to
          generate future profitable  operations and receive continued financial
          support from its stockholders  and other  investors.  The consolidated
          financial  statements do not include any adjustments that might result
          from the  outcome of this  uncertainty,  including  being  required to
          realize its assets and  discharge  its  liabilities  in other than the
          normal  course  of  business  and  at  amounts  differing  from  those
          reflected in the consolidated statements.

          Management's  plans include  generating future  profitable  operations
          from future  sales of the  retractable  syringe as well as  additional
          funding   from   stockholders   in  the  form  of   additional   share
          subscriptions.  There can be no  assurance  that a market will develop
          for the retractable  syringe or that additional  share financings will
          be  available.  Failure to obtain  adequate  financing  will cause the
          Company to curtail operations and the Company's ability to continue as
          a going concern will be impaired.  The outcome of these  uncertainties
          cannot be determined at this time.

     b)   Basis of presentation

          The  consolidated  financial  statements  include the  accounts of the
          Company and its wholly owned subsidiary. All significant inter-company
          balances and transactions have been eliminated.

          The  financial  information  presented as at August 31, 2002,  for the
          three  months  ended  August 31, 2002 and 2001 and for the period from
          inception  (March 17, 1997) to August 31, 2002 is unaudited,  however,
          in the opinion of management,  all adjustments  (consisting  solely of
          normal recurring  items) necessary for the fair  presentation of these
          unaudited amounts in conformity with accounting  principles  generally
          accepted  in the  United  States  of  America  have been  made.  These
          unaudited interim consolidated  financial statements should be read in
          conjunction with the annual consolidated  financial statements for the
          year ended May 31, 2002 filed under Form 10-KSB.

     c)   Management estimates

          The preparation of financial  statements in conformity with accounting
          principles generally accepted in the United States of America requires
          management to make estimates and assumptions  that affect the reported
          amounts of assets and liabilities and disclosures of contingent assets
          and  liabilities  at the  date  of the  financial  statements  and the
          reported amounts of revenues and expenses during the reporting period.
          Actual results could differ from those estimates.




                                       F-8
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
($ United States)

(Unaudited)

================================================================================

2.   Share subscriptions
------------------------

     During the three months ended August 31, 2002,  the Company  received share
     subscriptions for 14,546 common shares at $4.40 per share for cash proceeds
     of $64,000,  17,454 common  shares at an assigned  value of $3.25 per share
     for  consulting  services,  500  common  shares at $3.25 per share for cash
     proceeds of $1,625,  18,231 common shares at an assigned value of $2.70 per
     share for  consulting  services  of $8,933 and cash  proceeds  of  $40,290,
     20,000 common shares at an assigned value of $2.61 per share for consulting
     services of $8,000 and cash  proceeds of $44,200,  and 165 common shares at
     $2.485 per share for cash proceeds of $410.  All per share values are based
     on the  market  price of the  Company's  common  shares  at the date of the
     transaction.  All subscription  proceeds were received by the Company prior
     to August 31, 2002.

3.   Commitments:
-----------------

     (a)  Stockholders  who  acquired  99,933  common stock from the Company for
          aggregate proceeds of approximately $263,573, exercised their right of
          rescission.  As at August 31, 2002 the  company has repaid  $46,226 of
          the  $263,573.  During the three months  ended August 31, 2002,  5,000
          shares  were  retracted  from the  rescission  offer  by the  original
          purchaser, resulting in a decrease in the liability of $5,000 as these
          shares  were  originally  issued at $1 per share.  These  shares  were
          returned to the  shareholder  and removed  from  treasury  stock.  The
          remaining  $212,347  is  included  in  accounts  payable  and  accrued
          liabilities on the consolidated  balance sheet. As at August 31, 2002,
          18,702 shares were cancelled and the remaining 76,231 shares are being
          held in treasury.  The Company does not have sufficient funds to repay
          this liability at this time.

     (b)  The Company has signed an offer to purchase  additional  office  space
          for  approximately  $604,000 with a planned occupancy date of April 1,
          2003. To date the Company has not secured the  necessary  financing to
          fund this acquisition.























                                       F-9
<PAGE>





Item 2.  Management's Discussion and Analysis or Plan of Operation
------------------------------------------------------------------

THIS  ANNUAL  REPORT  SPECIFIES  FORWARD-LOOKING  STATEMENTS  OF OUR  MANAGEMENT
("FORWARD-LOOKING  STATEMENTS") INCLUDING,  WITHOUT LIMITATION,  FORWARD-LOOKING
STATEMENTS   REGARDING  OUR   EXPECTATIONS,   BELIEFS,   INTENTIONS  AND  FUTURE
STRATEGIES.   FORWARD-LOOKING   STATEMENTS  ARE  STATEMENTS  THAT  ESTIMATE  THE
HAPPENING   OF  FUTURE   EVENTS   AND  ARE  NOT  BASED  ON   HISTORICAL   FACTS.
FORWARD-LOOKING  STATEMENTS  MAY BE  IDENTIFIED  BY THE  USE OF  FORWARD-LOOKING
TERMINOLOGY,  SUCH AS "COULD",  "MAY", "WILL",  "EXPECT",  "SHALL",  "ESTIMATE",
"ANTICIPATE",  "PROBABLE", "POSSIBLE", "SHOULD", "CONTINUE", "INTEND" OR SIMILAR
TERMS,   VARIATIONS  OF  THOSE  TERMS  OR  THE  NEGATIVE  OF  THOSE  TERMS.  THE
FORWARD-LOOKING  STATEMENTS  SPECIFIED IN THIS  QUARTERLY  REPORT FOR THE 10-QSB
HAVE BEEN COMPILED BY US ON THE BASIS OF  ASSUMPTIONS  MADE BY US AND CONSIDERED
BY US TO BE REASONABLE. OUR FUTURE OPERATING RESULTS, HOWEVER, ARE IMPOSSIBLE TO
PREDICT AND NO  REPRESENTATION,  GUARANTY,  OR  WARRANTY IS TO BE INFERRED  FROM
THOSE FORWARD-LOOKING STATEMENTS.

THE ASSUMPTIONS USED FOR PURPOSES OF THE  FORWARD-LOOKING  STATEMENTS  REPRESENT
ESTIMATES OF FUTURE EVENTS AND ARE SUBJECT TO UNCERTAINTY AS TO POSSIBLE CHANGES
IN ECONOMIC,  LEGISLATIVE,  INDUSTRY, AND OTHER CIRCUMSTANCES.  AS A RESULT, THE
IDENTIFICATION AND INTERPRETATION OF DATA AND OTHER INFORMATION AND THEIR USE IN
DEVELOPING  AND SELECTING  ASSUMPTIONS  FROM AND AMONG  REASONABLE  ALTERNATIVES
REQUIRE THE EXERCISE OF JUDGMENT.  TO THE EXTENT THAT THE ASSUMED  EVENTS DO NOT
OCCUR, THE OUTCOME MAY VARY SUBSTANTIALLY FROM ANTICIPATED OR PROJECTED RESULTS,
AND,  ACCORDINGLY,  NO  OPINION  IS  EXPRESSED  ON THE  ACHIEVABILITY  OF  THOSE
FORWARD-LOOKING   STATEMENTS.  NO  ASSURANCE  CAN  BE  GIVEN  THAT  ANY  OF  THE
ASSUMPTIONS RELATING TO THE FORWARD-LOOKING  STATEMENTS SPECIFIED IN THIS REPORT
ARE ACCURATE,  AND WE ASSUME NO  OBLIGATION  TO UPDATE ANY SUCH  FORWARD-LOOKING
STATEMENTS.

Our Development
---------------

L.O.M.  Medical  International Inc. was incorporated in the State of Delaware on
March 17, 1997. Our executive  offices are located at #3-1482  Springfield Road,
Kelowna, B. C., Canada V1Y 5V3. Our telephone number is 250.762.7552.

For purposes of  clarification,  all dollar amounts  specified in this Quarterly
Report on Form  10-QSB are in the  currency  of the United  States.  Anytime the
symbol "CDN" is used, it refers to the currency of Canada.

Our Business
------------

We were  incorporated for the purpose of researching and developing  health care
products.  Our goal is to become an  innovator  and  provider  of a  retractable
syringe  ("Syringe")  and related  products and  technologies to the health care
market.  We have  successfully  patented and  licensed  products in 70 countries
including the United States and Canada and continue to maintain  these  patents.
We plan to develop  new and  improved  products  and  provide  the  health  care
industry with better, safer products throughout the world.






                                        2
<PAGE>




The Retractable Syringe
-----------------------

We believe the Syringe will change standard  disposal methods for used syringes.
The Syringe has been developed to function as a standard hypodermic syringe that
we believe is safer to the caregiver or health care worker.  We believe that the
Syringe's unique design will allow health care providers to avoid direct contact
with used needles.  The Syringe is covered by United States Patent No. 5,868,713
dated  February  9,  1999,  and  international  patents  have  been  filed in 84
different countries.

Once the needle of the  Syringe is  injected,  the user  simply has to press the
plunger  top gently  with his or her thumb to  automatically  retract the needle
into its own sealed chamber. The needle is now hidden where it remains locked in
place and cannot be used  again.  The  Syringe  does not  require a health  care
worker  to use both  hands to  retract  the  needle  after it has been  used and
withdrawn  from the patient.  The Syringe will be produced in standard  industry
sizes from 1CC to 20 CC, inclusive.

We intend to promote  the Syringe as a safer and less  risk-oriented  instrument
for hospital  staff and health care  workers.  We are  optimistic  that doctors,
nurses,  and other health care workers will  recognize and appreciate the safety
features of the Syringe because of its ease of "use-and-disposal" and its unique
"contamination-prevention"  characteristics.  We currently  have no contracts to
sell the  Syringe  and  there  are no  guarantees  as to the  timing of any such
contracts in the future.

We anticipate that the products and technologies that we develop will be offered
to distributors on a worldwide basis, with an initial emphasis in Canada and the
United  States.  We hope  that our new  product  and  technology  ideas  will be
generated through active dialogues among our potential customers and our network
of  scientific   advisors.   We  also  hope  to   participate  in  national  and
international   conferences   and  generate   reviews  in  selected   scientific
literature.

We interact with a network of scientific advisors within the industry, including
members of academic institutions,  as well as potential customers. We anticipate
that these  relationships  will enable us to identify the  specialized  needs of
those potential  customers and provide  innovative and  commercially  acceptable
products and  technologies.  At this time,  our  relationships  with  scientific
advisors and academic  institutions  are limited to advisory  relationships.  We
anticipate  testing the Syringe in  conjunction  with teaching  universities  in
Canada, Britain, and other constituents of the United Kingdom.

Our engineering  personnel are continuing the additional patenting of the L.O.M.
retractable syringe. We are ensuring that patents correctly protect every detail
pertaining to the syringe.

The 3cc syringe is ready for production.  The production  molds will be modified
for these size changes.  Other syringe sizes 1cc, 1.5cc,  2cc, 5cc, and 10cc are
ready for prototyping.  The extensive  designing of the syringe  components have
utilized the shared parts  between all sizes,  thus  minimizing  overall cost of
total parts.

The Company has begun design  plans for an assembly  line to produce the syringe
in commercial quantities.  The plan is being developed jointly by management and
a consulting  engineer.  The assembly  line plan  contemplates  features such as
programmable robotic systems with machine vision technology and high speed parts
flexible  feeder systems.  The Company is also  contemplating  injector  molding
machines,  sterilization  units,  packaging  equipment and other components that
comprise the planned assembly line.

During  the  next  12  months  we  anticipate   increasing   our  staff  as  the
pre-production  of the  syringe  moves  forward.  Dr.  Simon  Wood has agreed to
supervise our research and development department.  Currently, he bills us on an
hourly basis for work completed.  There is no written  contract with him at this
time. We have  contracted  with Kevin Conway,  a mid-level  engineer for certain
services.  Mr.  Conway  performs  subcontract  work on an  hourly  basis.  He is
assisting with CAD-CAM requirements  relating to the development of the Syringe.
We have contracted with Jim MacLean to perform the duties of Vice President. Jim
will be  assisting  the  company in raising  capital for the  production  of the
retractable syringe.


                                        3
<PAGE>




To satisfy our  financial  obligations  pursuant to agreements to which we are a
party during the next few months we require additional cash resources.  From our
inception on March 17, 1997,  to August 31, 2002,  we have  incurred  $1,311,917
related  to the  development  of the  Syringe,  including  the proof of  concept
prototype and molds for the test syringes.

We are not currently  producing  commercial  quantities of products or currently
supplying any services to any third  parties.  No assurance can be given that we
will,  on a timely  basis,  be able to make the  transition  from  manufacturing
testing   quantities  of  the  Syringe  to  commercial   production   quantities
successfully or arrange for contract manufacturing.

We anticipate  contracting for the first 2 years of commercial production of the
Syringe. At the end of the second year of production,  we anticipate engaging in
significant   discussions  regarding  the  potential  construction  of  our  own
production facility. We recognize that the construction of a production facility
will be  contingent  upon us having  reached  our sales and profit  projections.
Negotiations to establish  manufacturing  facilities in Ireland have begun,  but
have not progressed beyond the preliminary discussions.

The Eye Care System
-------------------

We have  invented  and  developed an  insertion  and storage  device for contact
lenses  (the "Eye Care  System"),  which is a method of handling  and  inserting
contact lenses.

We have produced 33,000 units of our eye care inserters,  which will be used for
demonstrations.  As such, we have not inventoried the units but we have expensed
them in the  past  financial  statements.  We  currently  have  the  ability  to
subcontract  out for the  production  of  commercial  quantities of our eye care
products. We currently have dies with an output capacity of 150,000 units. There
is a second set of dies designed  that will have a 300,000 unit  capacity  which
would allow the  production of a total of 450,000 units of eye care products per
month.

We have FDA  approval  to market  our line of eye care  products  in the  United
States and the  necessary  Canadian  approval  to market  eye-care  products  in
Canada.  We are reviewing various contracts with third parties to market the Eye
Care System in Canada, as well as the United States.

We plan to focus our  activities  over the next twelve months on the  production
and introduction of the Syringe.  When that is finalized,  we will implement our
marketing plan for the Eye Care System products.

Skin Care Products
------------------

At this time we are reorganizing our approach to our skin care products. We will
not be pursuing this area aggressively until we are producing the syringe.

Genetic Patents
---------------

We are currently  negotiating  licensing  agreements  with the owners of various
patents on genetic  vectors.  As of August 31, 2002, we have advanced $54,680 to
the patent owners. Given the uncertainty  regarding the future recoverability of
these advances we wrote these advances off in our 2002 fiscal year.












                                        4
<PAGE>




Business of Our Subsidiary
--------------------------

There has been no activity in the subsidiary  this quarter.  For the foreseeable
future the subsidiary will be inactive.

Future Capital Requirements
---------------------------

We will require additional cash to implement our business strategies,  including
cash for payment of increased  operating  expenses and our existing  obligations
and commitments. No assurance can be given, however, that we will have access to
the capital  markets in the  future,  or that  financing  will be  available  on
acceptable  terms to satisfy our cash  requirements  necessary to implement  our
business  strategies.  The  inability  to access the  capital  markets or obtain
acceptable  financing  could have a material  adverse  effect on our  results of
operations and financial condition.

Our forecast of the period of time during which our financial  resources will be
adequate to support our operations is a forward-looking  statement that involves
risks and  uncertainties,  and actual results could vary as a result of a number
of factors.

We anticipate  having to raise  additional  capital  during the next 3 months in
order to develop,  promote, produce and distribute our proposed products as well
as satisfy our existing obligations, including the liability disclosed in note 3
to the  financial  statements.  Such  additional  capital may be raised  through
additional  public  or  private  financings,  as well as  borrowings  and  other
resources.  To the extent  that  additional  capital is raised  from the sale of
equity or  equity-related  securities,  the issuance of those  securities  could
result in dilution of our stockholders.

The Company has also signed an offer to  purchase  additional  office  space for
approximately  $604,000 with a planned  occupancy date of April 1, 2003. To date
the Company has not secured the necessary financing to fund this acquisition.

There can be no assurance that additional funding will be available on favorable
terms, if at all. If adequate funds are not available  within the next 3 months,
we will be required to curtail  operations  significantly  or to obtain funds by
entering  into  arrangements  with  collaborative  partners  or others  that may
require us to  relinquish  rights to certain of our  products  that we would not
otherwise relinquish.

Business Risks
--------------

We are exposed to a variety of business risks, some of which are inherent to all
competitive commercial enterprises,  and others that are specific to the medical
products  industry.  We will  continue to endeavor  to limit all  specific  risk
factors by our operations and financial strategies.





















                                        5
<PAGE>




Financial Risks
---------------

Our business  plans are  aggressive in nature.  Continued  rapid  expansion will
consume valuable working capital and result in significant  demand for cash from
operations  during  the next few  quarters.  We  expect  that  existing  capital
resources  and  contributions  from profits will not be  sufficient  to fund our
business plans as represented  without receiving  additional funds from external
sources.

Business Cycles and Risks of Cost Overruns
------------------------------------------

The  sale  and  implementation  of our  products  involve  a  reasonable  market
penetration.  Failure to secure reasonable market penetration could have adverse
effects on our business, results of operations and its financial condition.

Fluctuations in Financial Results
---------------------------------

Our operating  results will  fluctuate,  depending on factors such as the demand
for products,  the size and timing of contracts,  new products and enhancements,
price  competition,  changes in  operating  expenses and  personnel  and general
economic factors.  Therefore,  actual financial  results may vary  significantly
from those projected by us.

Third-Party Claims for Infringement
-----------------------------------

We are not aware that any of our products infringe on the proprietary  rights of
third parties.  There can be no assurance,  however, that third parties will not
claim such  infringements by us with respect to current or future products.  Any
such claims,  with or without merit,  could be time consuming,  result in costly
litigation, or cause product or shipment delays. Any of the foregoing could have
adverse effects on our business, results of operations or financial condition.

Dependence of Single Product Line
---------------------------------

Concentration  of sales in a single product line for the medical health industry
represents a substantial risk, should market conditions deteriorate.

Foreign Currency
----------------

Our business plans are primarily focused on the penetration in the United States
and subsequently worldwide markets; therefore, we will be subject to the risk of
foreign currency fluctuations.

Competition and Sales Channels
------------------------------

Several  companies  compete  with us in the  syringe  market and there are a few
competitors  in the safety syringe  market.  Most are  substantially  larger and
possess greater  financial  resources than we do. Our future  success,  however,
relies on achieving superior product development by greater concentration on the
needs of the market and faster response to evolving customer requirements. There
can be no  assurance,  however,  that  competitors  will  not  develop  products
superior to our products or achieve greater market  acceptance due to marketing,
sales channels or other factors.

Dependence on Large Distributors
--------------------------------

We will rely in part on business  partners for the distribution of our products.
This includes a few large  distributors in the United States. We may be impacted
by negative business cycles or events  experienced by these  distributors.  This
may result in a short or long term reduction in revenue.







                                        6
<PAGE>




Human Resource Risks and Growth
-------------------------------

Our  success is  largely  dependent  on the  performance  of its key  employees.
Failure to attract and retain key employees with necessary  skills could have an
adverse  impact upon our growth and  profitability.  Our business is expected to
increase  rapidly  during the next three  years.  This  increase  will result in
substantial  growth in the number of  employees,  the scope of our operating and
financial systems and the geographic area of our operations.  This increases the
responsibilities for both existing and new management personnel.  Our ability to
support the  projected  growth of our  business  will be  dependent  upon having
highly  trained  personnel  in place to conduct  pre-sales  activities,  product
implementation and other customer support services. Our future operating results
will  depend on the ability of our key  managers  and  employees  to continue to
implement and improve our operational,  customer support and financial  systems.
There can be no  assurance  that we will be able to manage any future  expansion
successfully,  and, if we cannot, this could adversely affect the results of our
operations and our financial condition.

Production and Quality Control
------------------------------

The manufacturing of products involves a number of steps and requires compliance
with  stringent  quality  control   specifications  imposed  on  us  by  various
regulators.  We may not be able to replace manufacturing capacity quickly, if we
were unable to use our manufacturing  facilities as a result of a fire,  natural
disaster (including  earthquake),  equipment failure or other difficulty,  or if
such  facilities  are  deemed not in  compliance  with the  various  regulators'
requirements  and  the  non-compliance  could  not  be  rapidly  rectified.  The
inability or reduced  capacity to  manufacture or have  manufactured  any of our
products  would have a material  adverse  effect on the  business and results of
operations.

Government Standards and Regulations
------------------------------------

Our  products  will be subject to  numerous  foreign  government  standards  and
regulations  that are  continually  being amended.  Although we will endeavor to
satisfy foreign  technical and regulatory  standards,  there can be no assurance
that our products will comply with foreign government standards and regulations,
or changes  thereto,  or that it will be cost effective to redesign our products
to  comply  with such  standards  or  regulations.  Our  inability  to design or
redesign products to comply with foreign standards could have a material adverse
effect on our business, financial condition and results of operations.

Product Liability Risk
----------------------

Our  business  and the  business of our  subsidiary  will expose us to potential
product  liability  risks that are  inherent in the testing,  manufacturing  and
marketing  of medical  products.  We do not  currently  have  product  liability
insurance,  and  there  can be no  assurance  that we will be able to  obtain or
maintain such insurance on acceptable terms or, if obtained, that such insurance
will provide adequate coverage against potential liabilities.

We face an inherent  business  risk of exposure to product  liability  and other
claims,  in the event that the  development or use of our technology or products
is alleged to have  resulted  in adverse  effects.  That risk  exists  even with
respect to those  products  that are  manufactured  in  licensed  and  regulated
facilities or that otherwise  possess  regulatory  approval for commercial sale.
There can be no  assurance  that we will  avoid  significant  product  liability
exposure.  There can be no  assurance  that  insurance  will be available in the
future on commercially  reasonable terms, or at all, or that such insurance will
be  adequate  to pay  potential  product  liability  claims  or  that a loss  of
insurance  or the  assertion  of a product  liability  claim or claims would not
materially  adversely  affect our business,  financial  condition and results of
operations.

Although  we have  taken,  and  will  continue  to  take,  what we  believe  are
appropriate  precautions,   there  can  be  no  assurance  that  we  will  avoid
significant  liability  exposure.  An  inability  to  obtain  product  liability
insurance at acceptable cost or to otherwise  protect against  potential product
liability claims could prevent or inhibit the commercialization of our products.
A product  liability claim could have a material adverse effect on our business,
financial condition and results of operations.

                                        7
<PAGE>




Liquidity and Capital Resources
-------------------------------

We  believe we have  raised  enough  capital  to allow us to meet our  financial
obligations  for a  period  of at least 3  months  from  August  31,  2002,  not
including  our  current  obligations,  aggregating  $212,347  under the  British
Columbia  Securities  Commission  rescission  offer.  However,  this three-month
forecast is a forward-looking  statement that involves risks and  uncertainties.
Actual results could differ  significantly as a result of these uncertainties as
the forecast assumes on-going support from creditors,  including the obligations
under the rescission offer, and shareholders.

We had cash  resources of $147,458 at August 31, 2002.  At May 31, 2002,  we had
cash  resources of $142,114.  At August 31, 2002,  total current  assets of were
$178,626 and total current  liabilities of $296,184.  At August 31, 2002,  total
current liabilities exceeded total current assets by $117,558.  At May 31, 2002,
total current assets were of $169,282 and total current liabilities of $319,537.
At May 31, 2002,  total current  liabilities  exceeded  total current  assets by
$150,255.  Because we are not generating any revenues,  our only external source
of  liquidity  is  the  sale  of our  capital  stock.  We  have  no  contractual
obligations for capital  purchases or any other  commitments at this time, other
than an offer to purchase  additional  office space for  approximately  $604,000
with a planned  occupancy  date of April 1, 2003.  To date the  Company  has not
secured the necessary financing to fund this acquisition.

Management's plans include  generating future profitable  operations from future
sales of the retractable syringe as well as additional funding from stockholders
in the form of additional share subscriptions.  There can be no assurance that a
market  will  develop  for the  retractable  syringe  or that  additional  share
financings will be available.  Failure to obtain  adequate  financing will cause
the Company to curtail operations.

Critical Accounting Policies
----------------------------

The Company's  discussion and analysis of its financial condition and results of
operations,  including the  discussion on liquidity and capital  resources,  are
based upon the  Company's  financial  statements,  which have been  prepared  in
accordance with accounting  principles  generally accepted in the United States.
The  preparation  of these  financial  statements  requires  the Company to make
estimates and judgments that affect the reported amounts of assets, liabilities,
revenues  and  expenses,   and  related  disclosure  of  contingent  assets  and
liabilities.  On an ongoing  basis,  management  re-evaluates  its estimates and
judgments.  Actual results could differ from the estimates. The Company believes
the following critical accounting policy requires more significant  judgment and
estimates used in the preparation of the consolidated financial statements.

The  consolidated  financial  statements have been prepared on the going concern
basis, which assumes the realization of assets and liquidation of liabilities in
the normal course of operations.  If the Company were not to continue as a going
concern,  it  would  likely  not be able to  realize  on its  assets  at  values
comparable to the carrying  value or the fair value  estimates  reflected in the
balances set out in the preparation of the consolidated financial statements. As
described  elsewhere  in  this  report,  at May  31,  2002,  there  are  certain
conditions that currently exist which raise substantial doubt about the validity
of this assumption.  While the Company  anticipates  raising  additional funding
through  future  profitable  operations and the sale of share  subscriptions  to
remove the  substantial  doubt,  these funds are not  assured.  Failure to raise
additional  funds may result in the  Company  curtailing  operations  or writing
assets and liabilities down to liquidation values, or both.

Results of Operations
---------------------

We have not yet realized any revenues from  operations.  The loss from March 17,
1997  (inception) to August 31, 2002, was  $4,128,949.  The loss for the 3-month
period ended August 31,  2002,  was $194,721  compared to a loss of $308,228 for
the 3-month period ended August 31, 2001.  Such losses were primarily the result
of product development and operational expenditures.



                                        8
<PAGE>




In the  current  3-month  period the loss has  decreased  compared  to the prior
comparable  period  because we are  restricting  outflow of funds  until we have
additional capitalization.  During the 3-month period ending August 31, 2002, we
have paid $23,103 with regards to developing the Syringe, including a prototype,
compared  to $231,316  incurred  during the  3-months  ending  August 31,  2001.
General and  administrative  expenses for the 3-month  period  ending August 31,
2002 have  increased  from the 3-month  period  ending August 31, 2001 due to an
increase in legal and  accounting  fees and  consulting  fees.  We have incurred
$25,018 in legal and  accounting  fees for the 3-month  period ending August 31,
2002  compared to $20,643 for the 3-month  period  ending  August 31, 2001.  The
increase in legal and  accounting  fees is due mainly to  increase in  reporting
requirements.  Consulting fees for the 3-month period ending August 31, 2002 was
$83,806  compared to $33,912  for the 3-month  period  ending  August 31,  2001,
respectively.  The increase in consulting  fees is the result of incurred  costs
related to achieving funding requirements.

For the 3-month  period  ended  August 31, 2002,  capital  stock and  additional
paid-in  capital  have  increased  by  $39,375  since  May 31,  2002  due to the
conversion of stock subscriptions to 10,693 common shares.
















































                                        9
<PAGE>





                                     Part II


Item 1.  Legal Proceedings
--------------------------

Litigation Involving Our Subsidiary.
------------------------------------

None.

British Columbia Securities Commission Rescission Offer.
--------------------------------------------------------

As of August 31, 2002,  stockholders  holding  94,933 shares of our common stock
with a paid up capital of $258,573 have exercised their right of rescission.  As
of August 31,  2002,  $46,226  had been paid  regarding  the  rescission  offer,
leaving  $212,347  remaining to be paid, which has been recorded in our accounts
payable and accrued liabilities.











































                                       10
<PAGE>




Item 2.  Changes in Securities
------------------------------

Warrants.
---------

We have offered to all  shareholders of record at June 30, 2001, one warrant for
every 2 shares held by each  shareholder.  Each  warrant  entitles the holder of
such warrant to purchase one share of our common stock for $5.00 per share. Each
warrant  expires 90 days after the first  transaction in our common stock occurs
on a public market.

Stock Options.
--------------

Our Board of Directors  has adopted a stock option plan ("Stock  Option  Plan").
The Stock Option Plan is designed to retain  qualified and  competent  officers,
employees and directors of the Company.  Our Board of Directors,  or a committee
thereof,  shall administer the Stock Option Plan and is authorized,  in its sole
and absolute  discretion,  to grant  options to all of our  eligible  employees,
officers and  directors  (whether or not employed by us).  During the year ended
May 31, 2001,  340,417 stock  options were granted in accordance  with the Stock
Option Plan. Under SFAS 123, compensation cost of $295,269 has been recorded for
those options issued to consultants to August 31, 2002. Options granted pursuant
to the Stock Option Plan will be exercisable  within the period specified in the
respective stock option agreements.  Options granted under the Stock Option Plan
will not be exercisable  after the expiration of ten (10) years from the date of
grant  for  shareholders  with less  than 10%  ownership  and five (5) years for
shareholders  with 10% or more share ownership.  The Stock Option Plan will also
authorize  us to make  loans to  optionees  to  enable  them to  exercise  their
options.

Share Issuances.
----------------

During the three months ended August 31, 2002,  10,693 common shares were issued
on conversion of stock subscription.


Item 3.  Defaults Upon Senior Securities
----------------------------------------

None.


Item 4.  Submission of Matters to Vote of Security Holders
----------------------------------------------------------

None.


Item 5.
-------



Item 6.  Exhibits and Reports on Form 8-K
-----------------------------------------

Dr.  Punnet  resigned as a director  effective  April 16, 2002.  Peter  McFadden
resigned as CFO and Vice President  effective  August 15th 2002.  Tanya Sedlacek
became CFO on August 15th 2002.











                                       11
<PAGE>





                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


Dated:  September 15, 2002                    L.O.M. Medical International, Inc.


                                        By:   /s/ John Klippenstein
                                              ---------------------------------
                                              John Klippenstein
                                        Its:  President














































                                       12
<PAGE>




                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of L.O.M.  Medical  International,  Inc.
(the "Company"),  on form 10-QSB for the three months ending August 31, 2002, as
filed with the  Securities  and  Exchange  Commission  on the date  hereof  (the
"Report"),  I,  John  Klippenstein,  Chief  Executive  Officer  of the  Company,
certify,  pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:

1.   The Report fully complies with the requirements of Section 13(a) or Section
15(d) of the Securities Exchange Act of 1934, and

2.   The information  contained in the Report fairly  presents,  in all material
respects, the financial condition and results of operations of the Company.


September 15, 2002                             By:  /s/ John Klippenstein
                                                    ---------------------------
                                                    John Klippenstein
Its:  Chief Executive Officer




























                                       13